Watson (WPI) Affirms Patent Claims on Sanctura XR Were Ruled Invalid

Watson Pharmaceuticals, Inc. (NYSE: WPI) confirmed that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978 (the '978 Patent), 7,759,359 (the '359 Patent), 7,781,448 (the '448 Patent), 7,781,449 (the '449 Patent) and 7,763,635 (the '635 Patent) for Sanctura XR (trospium chloride extended-release capsules) are invalid.

Watson's Abbreviated New Drug Application for a generic version of Sanctura XR is pending with the Food and Drug Administration.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sky Quarry names Heidi Bowman as CFO
• Sky Century Investment responds to OTC Markets stock promotion inquiry
• Westlake Corp adds dual listing on NYSE Texas exchange